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Ho
CaOBJECTIVES The aim of this study was to assess the safety of the concurrent administration of a clopidogrel and
prasugrel loading dose in patients undergoing primary percutaneous coronary intervention.
BACKGROUND Prasugrel is one of the preferred P2Y12 platelet receptor antagonists for ST-segment elevation
myocardial infarction patients. The use of prasugrel was evaluated clinically in clopidogrel-naive patients.
METHODS Between September 2009 and October 2012, a total of 2,023 STEMI patients were enrolled in the
COMFORTABLE (Comparison of Biomatrix Versus Gazelle in ST-Elevation Myocardial Infarction [STEMI]) and the SPUM-
ACS (Inﬂammation and Acute Coronary Syndromes) studies. Patients receiving a prasugrel loading dose were divided into
2 groups: 1) clopidogrel and a subsequent prasugrel loading dose; and 2) a prasugrel loading dose. The primary safety
endpoint was Bleeding Academic Research Consortium types 3 to 5 bleeding in hospital at 30 days.
RESULTS Of 2,023 patients undergoing primary percutaneous coronary intervention, 427 (21.1%) received clopidogrel
and a subsequent prasugrel loading dose, 447 (22.1%) received a prasugrel loading dose alone, and the remaining received
clopidogrel only. At 30 days, the primary safety endpoint was observed in 1.9% of those receiving clopidogrel and a sub-
sequent prasugrel loading dose and 3.4% of those receiving a prasugrel loading dose alone (adjusted hazard ratio [HR]:
0.57; 95% conﬁdence interval [CI]: 0.25 to 1.30, p ¼ 0.18). The HAS-BLED (hypertension, abnormal renal/liver function,
stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol concomitantly)
bleeding score tended to be higher in prasugrel-treated patients (p¼0.076). The primary safety endpoint results, however,
remained unchanged after adjustment for these differences (clopidogrel and a subsequent prasugrel loading dose vs.
prasugrel only; HR: 0.54 [95% CI: 0.23 to 1.27], p ¼ 0.16). No differences in the composite of cardiac death, myocardial
infarction, or stroke were observed at 30 days (adjusted HR: 0.66, 95% CI: 0.27 to 1.62, p ¼ 0.36).
CONCLUSIONS This observational, nonrandomized study of ST-segment elevation myocardial infarction patients sug-
gests that the administration of a loading dose of prasugrel in patients pre-treated with a loading dose of clopidogrel is not
associated with an excess of major bleeding events. (Comparison of Biomatrix Versus Gazelle in ST-Elevation Myocardial
Infarction [STEMI] [COMFORTABLE]; NCT00962416; and Inﬂammation and Acute Coronary Syndromes [SPUM-ACS];
NCT01000701). (J Am Coll Cardiol Intv 2015;8:1064–74) © 2015 by the American College of Cardiology Foundation.m the *Department of Cardiology, Bern University Hospital, Bern Switzerland; yUniversity Heart Center, Cardiology, University
spital, Zurich, Switzerland; zInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; xCardiac
theterization Laboratory, Rigshospitalet, Copenhagen, Denmark; kDivision of Cardiology, University Hospital, Geneva,
AB BR E V I A T I O N S
AND ACRONYM S
ACS = acute coronary
syndrome
BARC = Bleeding Academic
Research Consortium
CI = conﬁdence interval
HR = hazard ratio
IPTW = inverse probability of
treatment weighted
PCI = percutaneous coronary
intervention
PRU = platelet reactivity unit
STEMI = ST-segment elevation
myocardial infarction
TIMI = Thrombolysis In
Myocardial Infarction
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1065R apid, potent, and consistent inhibition ofplatelet aggregation is a cornerstone inthe treatment of patients with acute ST-
segment elevation myocardial infarction (STEMI)
undergoing primary coronary intervention (PCI) to
complement optimal epicardial and myocardial re-
perfusion while protecting against recurrent ischemic
events (1). The administration of a clopidogrel loading
dose before primary PCI has been shown to reduce
ischemic events, with a 600-mg loading dose
emerging as the preferred regimen (2,3). Compared
with clopidogrel, prasugrel provides a more rapid
onset and more potent and consistent inhibition
of platelet aggregation (4,5). In STEMI patients under-
going PCI, prasugrel has been shown to be more
effective than clopidogrel by reducing the risk of
cardiovascular mortality, myocardial infarction, and
stroke as well as stent thrombosis (6). Of note,
improved efﬁcacy in STEMI patients was not associ-
ated with an increased risk of bleeding throughout
15 months of follow-up. Recent guidelines for the
management of STEMI patients recommend prasugrel
over clopidogrel in patients undergoing primary PCI,
without commenting on the use of prasugrel in clopi-
dogrel pre-treated patients (7,8). Clopidogrel, howev-
er, is frequently administered upstream, even in
STEMI patients. The administration of a prasugrel
loading dose in patients already exposed to clopidog-
rel has raised concerns about bleeding and potential
drug interactions, thereby potentially offsetting
beneﬁcial effects in terms of efﬁcacy. We thereforeSwitzerland; {Cardiology Department, Triemlispital, Zurich, Switzerland;
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regimens consisting of clopidogrel and a
subsequent prasugrel loading dose and a pra-
sugrel loading dose alone using pre-speciﬁed
endpoint deﬁnitions for safety and efﬁcacy
with assessment of adverse events by an in-
dependent adjudication committee in a large,
contemporary population of STEMI patients
undergoing primary PCI. Because no effect
of a concomitant loading dose of clopidogrel
and prasugrel is expected during the mainte-
nance period of the therapy, the endpoints
were assessed at hospital discharge and at
30 days.
METHODSPATIENT POPULATION. Patients with STEMI were
considered when participating in the COMFORTABLE
(Comparison of Biomatrix Versus Gazelle in ST-
Elevation Myocardial Infarction [STEMI]) trial or in
the SPUM-ACS (Inﬂammation and Acute Coronary
Syndromes) trial and receiving either a prasugrel
loading dose alone or a clopidogrel loading dose and a
subsequent prasugrel loading dose. The design of the
COMFORTABLE trial has been reported elsewhere
(9,10). Brieﬂy, this was a multicenter, randomized,
assessor-blinded superiority trial comparing a novel
biodegradable polymer–based biolimus-eluting stent
with a bare metal stent in STEMI patients undergoing
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1066older with acute ST-segment elevation of at least
1 mm in $2 contiguous leads, true posterior myocar-
dial infarction, or new left bundle branch block were
eligible for randomization in the presence of at least
1 culprit lesion in the infarct vessel. Exclusion criteria
were the presence of mechanical complications of
acute myocardial infarction, known allergy to any
study medication, use of vitamin K antagonists,
planned surgery unless dual antiplatelet therapy
could be maintained throughout the perisurgical
period, history of bleeding diathesis or known co-
agulopathy, pregnancy, participation in another trial
before reaching the primary endpoint, inability to
provide informed consent, and noncardiac comorbid
conditions with a life expectancy <1 year.
The SPUM-ACS cohort study is a multicenter,
observational cohort study of patients presenting
with acute coronary syndrome (ACS) conducted at
4 Swiss university hospitals (in Bern, Geneva, Lau-
sanne, and Zurich). Inclusion criteria were the pres-
ence of an ACS and age older than 18 years. Exclusion
criteria comprised severe physical disability, inability
to comprehend study, and life expectancy <1 year.
For the purpose of the present analysis, all STEMI
patients included in the SPUM-ACS with the same
qualifying diagnostic criteria as in the COMFORT-
ABLE trial were selected. Both studies complied with
the Declaration of Helsinki and were approved by
local institutional ethics committees. All patients
provided written, informed consent.
PROCEDURES. In the COMFORTABLE trial, patients
were randomly assigned on a 1:1 basis to treatment
with biolimus-eluting stents made of a biodegrad-
able polylactic acid polymer (BioMatrix, Biosensors
Europe SA, Morges, Switzerland) or bare metal stents
of otherwise identical design (Gazelle, Biosensors
Europe SA). In SPUM-ACS STEMI patients, the use of a
newer generation drug-eluting stent was recom-
mended with the ﬁnal selection of stent type left to
the discretion of the operator. Before stent implan-
tation, thrombus aspiration was recommended in all
patients whenever aspiration was deemed technically
feasible (COMFORTABLE) or whenever thrombus was
angiographically visible (SPUM-ACS). During the
procedure, unfractionated heparin was administered
at a dose of at least 5,000 IE or 70 to 100 IE/kg or
alternatively bivalirudin. The use of glycoprotein
IIb/IIIa inhibitors was left to the discretion of the
operator. There was no recommendation regarding
the access route.
DRUG REGIMEN. In the COMFORTABLE study, ace-
tylsalicylic acid ($250 mg) was administered before
the procedure. The administration of a P2Y12 inhibitorloading dose (prasugrel 60 mg when available or,
alternatively, clopidogrel 600 mg) was recommended
as soon as the diagnosis of a STEMI was conﬁrmed by
pre-hospital electrocardiography. In centers where
prasugrel was available, a loading dose of 60 mg,
irrespective of pre-treatment with clopidogrel, was
systematically administered, followed by a mainte-
nance dose of 10 mg daily. Prasugrel, in addition to a
loading dose of clopidogrel, was administered in the
cath lab just before, during, or immediately after
primary PCI. Whenever clopidogrel was continued, a
daily dose of 75 mg was used. In the SPUM-ACS cohort
study, acetylsalicylic acid ($250 mg) was adminis-
tered before the procedure, and prasugrel was avail-
able at all SPUM-ACS centers since inclusion of the
ﬁrst patient. Administration of a P2Y12 inhibitor
loading dose (prasugrel 60 mg, when available or,
alternatively, clopidogrel 600 mg) was recommended
as soon as the diagnosis of a STEMI was conﬁrmed by
a pre-hospitalization 12-lead electrocardiogram. The
use of an initial loading dose of prasugrel 60 mg was
recommended in all patients irrespective of pre-
treatment with clopidogrel, followed by a daily dose
of 10 mg. Prasugrel, in addition to a loading dose of
clopidogrel, was administered in the cath lab just
before, during, or immediately after primary PCI.
Whenever clopidogrel was continued, a daily dose of
75 mg was prescribed. In patients 75 years of age or
older or those with a body weight <60 kg, a prasugrel
loading dose of 30 mg followed by a maintenance
dose of 5 mg daily was recommended in both studies.
Dual antiplatelet therapy was prescribed for at least
1 year in all patients. Study groups were deﬁned
according to the speciﬁc loading regimen: 1) clopi-
dogrel and a subsequent prasugrel loading dose; and
2) prasugrel loading dose alone. Patients who had
prasugrel subsequently replaced by clopidogrel or
vice versa were categorized according to the initial
loading dose regimen.
DATA MANAGEMENT. Independent study monitors
veriﬁed source data according to a pre-speciﬁed
monitoring plan in the COMFORABLE and SPUM-
ACS trials. Identical case record forms were used,
and data were stored in the same central database
(Cardiobase, CTU and Department of Cardiology, Bern
University Hospital, Switzerland and 2mT, Ulm,
Germany). Follow-up was scheduled at 30 days and
1 year.
CLINICAL ENDPOINTS. The primary safety endpoint
was BARC types 3 to 5 bleeding at 30 days, and the
secondary efﬁcacy endpoint was cardiac death,
nonfatal myocardial infarction, or stroke at 30 days.
Events were adjudicated by an independent clinical
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1067events committee. Endpoint deﬁnitions for both
COMFORTABLE and SPUM-ACS patients were iden-
tical. Bleeding was categorized according to the
consensus report from the BARC (11). In addition,
bleeding was classiﬁed according to the established
Thrombolysis In Myocardial Infarction (TIMI) (12)
and GUSTO (Global Utilization of Streptokinase and
Tissue Plasminogen Activator for Occluded Coronary
Arteries) trial (13) deﬁnitions. All deaths were con-
sidered cardiac unless an unequivocal noncardiac
cause was established. Deﬁnitions applied for spon-
taneous and periprocedural myocardial infarction are
listed in the Online Appendix. Ischemic stroke was
deﬁned as rapidly developing clinical signs of focal or
global disturbance of cerebral function lasting longer
than 24 h with imaging of an acute clinically relevant
brain lesion. Ischemic cerebral infarctions with con-
version to hemorrhage were categorized as ischemic
stroke. Intracerebral hemorrhage had to be conﬁrmed
by cerebral imaging. Stent thrombosis was deﬁned
according to the Academic Research Consortium
deﬁnitions (14).
STATISTICAL ANALYSIS. Categorical variables are
presented as number (%), with p values from a chi-
square or Fisher exact test and continuous vari-
ables as mean  SD, with p values from a pairwise
Student t test. Cox regression analysis of outcomesFIGURE 1 Flow Chart
STEMI ¼ ST-segment elevation myocardial infarction.at hospital discharge and 30-day follow-up using
time to ﬁrst event or composite events were used to
compare the clopidogrel and a subsequent prasugrel
loading dose versus a prasugrel loading dose alone
groups. We report hazard ratios (HRs) with 95%
conﬁdence intervals (CIs), both crude, and adjusted
as follows. 1) Ten datasets were created by multiple
imputation of missing data using chained equations.
2) In each dataset, an inverse probability of treat-
ment weighted (IPTW) was calculated using vari-
ables related, with p < 0.1, to the 3 exposure groups
in the original dataset (where the multinomial
treatments are the exposure to clopidogrel and a
subsequent prasugrel loading dose or prasugrel or
clopidogrel alone). The following baseline variables
were used for the IPTW: age, sex, weight, body mass
index, hypertension, cholesterolemia, family history
of coronary artery disease, peripheral arterial dis-
ease, history of stroke or transient ischemic attack,
history of malignancy, renal failure (estimated
glomerular ﬁltration rate <60), pain onset within
24 h, resuscitation, acute myocardial infarct loca-
tion, and procedural medications including unfrac-
tionated heparin, bivalirudin, low molecular weight
heparin, and glycoprotein II/IIIa antagonists.
3) Additional covariates not covered by the IPTW
and related, with p < 0.1, to BARC types 3 to 5
bleeding (which were history of coronary artery
TABLE 1 Baseline Characteristics
Clopidogrel þ
Prasugrel
(n ¼ 427)
Prasugrel
(n ¼ 447) p Value*
Age, yrs 59.8  11.0 58.5  11.0 0.08
Male 358 (83.8) 376 (84.1) 0.93
Body mass index, kg/m2 27.4  4.4 27.5  4.2 0.59
Cardiovascular risk factors
Diabetes mellitus 53 (12.4) 57 (12.8) 0.92
Insulin dependent 11 (2.6) 11 (2.5) 1.00
Hypertension 198 (46.4) 206 (46.1) 0.95
Hypercholesterolemia 214 (50.4) 268 (60.2) 0.004
Current smoker 204 (48.3) 220 (49.8) 0.68
Family history of CAD 92 (21.9) 106 (24.1) 0.47
Renal failure 21 (5.0) 49 (11.0) 0.001
Previous MI 36 (8.5) 29 (6.5) 0.30
Previous PCI 42 (9.8) 32 (7.2) 0.18
Previous CABG 12 (2.8) 8 (1.8) 0.37
Bleeding risk assessment
Age >75 yrs, history of stroke, or weight <60 kg 53 (12.4) 40 (8.9) 0.10
Laboratory ﬁndings
Anemia† 59 (14.5) 62 (14.7) 1.00
Thrombocytopenia‡ 24 (5.9) 15 (3.6) 0.14
Clinical presentation
Time from symptom onset to balloon
inﬂation #24 h
93.2 94.2 0.58
Killip class III/IV 15 (3.5) 24 (5.4) 0.19
Left ventricular ejection fraction§ 48.9  10.7 49.7  10.4 0.32
Electrocardiographic localization of MI 0.12
Anterior 155 (37.7) 188 (44.9)
Lateral 19 (4.6) 12 (2.9)
Inferior 214 (52.1) 203 (48.2)
Posterior or posterior and lateral 23 (5.6) 17 (4.1)
Right ventricular MI 32 (7.8) 23 (5.5) 0.21
Lesion complexity
Bifurcation treatment in any lesion 54 (12.7) 61 (13.9) 0.62
Long lesion ($28 mm)k 173 (41.3) 174 (40.4) 0.83
Values are mean  SD or n (%). *p values pairwise (prasugrel þ clopidogrel vs. prasugrel alone) from chi-square,
Fisher exact, Student t test, or Mann-Whitney U test. †Anemia was deﬁned as a hemoglobin concentration
<120 g/l for women and <130 g/l for men, according to the deﬁnition of the World Health Organization.
‡Thrombocytopenia was deﬁned as <150,000 platelets/ml. §Left ventricular function as assessed by angiography
at the time point of presentation or by echocardiography if angiography was not available. kLong lesion indicates
any lesion treated with a summed stent length of $20 mm.
CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease; MI ¼ myocardial infarction;
PCI ¼ percutaneous coronary intervention.
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1068bypass grafting, left ventricular ejection fraction) or
related, with p < 0.1, to the composite of cardiac
death, reinfarction, or stroke (which were insulin-
dependent diabetes, anemia, thrombocytopenia,
and Killip III or IV) were selected. 4) The adjusted
models on the multiple imputed datasets show HRs
weighting each patient with their IPTW and cor-
recting for the additional covariates study, history of
coronary artery bypass grafting, left ventricular
ejection fraction, insulin-dependent diabetes, ane-
mia, thrombocytopenia, and Killip III or IV. Risk
ratios with a continuity correction (with 95% CI)
and p values from the Fisher exact test are reportedin case of zero events. Adjusted analyses were
performed of the 2 primary outcomes only for in-
hospital events due to the low number of events
during the in-hospital time period. All statistical
analyses were 2-sided (with a ¼ 0.05) and were
performed with Stata 12.1 (StataCorp, College
Station, Texas).
RESULTS
PATIENT POPULATION. A total of 2,048 STEMI pa-
tients undergoing primary PCI in the context of the
COMFORTABLE and the SPUM-ACS trials were
included between September 2009 and October 2012
at 12 international sites. A total of 25 patients were
excluded because they did not receive either a pra-
sugrel or a clopidogrel loading dose. A total of 427
patients (21.1%) (258 COMFORTABLE and 169 SPUM-
ACS participants) received ﬁrst a loading dose of
clopidogrel at the time of ﬁrst medical contact fol-
lowed by a subsequent loading dose of prasugrel
before, during, or immediately after primary PCI
(clopidogrel and a subsequent prasugrel loading
dose group). A total of 447 patients (22.1%)
(212 COMFORTABLE and 235 SPUM-ACS participants)
received a loading dose of prasugrel at the time of ﬁrst
medical contact or before, during, or immediately af-
ter primary PCI (prasugrel alone group). The remaining
1,149 patients (56.8%) (668 COMFORTABLE and 463
SPUM-ACS participants) received a loading dose of
clopidogrel at the time of ﬁrst medical contact or
before, during, or immediately after primary PCI and
were not considered for the primary analysis. Follow-
up at 30 days was completed in 98.1% of patients
receiving clopidogrel and a subsequent loading dose of
prasugrel and 97.5% of patients receiving prasugrel
alone (Figure 1). Baseline characteristics of the
2 groups are presented in Table 1. Patients receiving
clopidogrel and a subsequent loading dose of prasu-
grel tended to be older and less frequently had dysli-
pidemia and renal failure. Procedural characteristics
are shown in Table 2. The baseline TIMI ﬂow tended to
be improved in patients receiving clopidogrel and a
subsequent prasugrel loading dose, and the average
stent diameter was smaller in the group receiving
clopidogrel and a subsequent loading dose of
prasugrel.
LOADING DOSE REGIMEN. Medications before, dur-
ing, or immediately after the primary PCI, at the time
of hospital discharge, at 30 days, and at 1-year follow-
up are summarized in Table 3, including details
regarding loading and maintenance doses. Bivali-
rudin and glycoprotein IIb/IIIa were less frequently
TABLE 2 Procedural Characteristics
Clopidogrel þ
Prasugrel
(n ¼ 427)
Prasugrel
(n ¼ 447) p Value*
No. of lesions treated 602 566
Lesions treated 1.41  0.73 1.28  0.60 0.003
Treated vessels
Left main coronary artery 7 (1.6) 2 (0.5) 0.10
Left anterior descending artery 185 (43.4) 209 (47.2) 0.28
Left circumﬂex artery 85 (20.0) 73 (16.5) 0.19
Right coronary artery 200 (46.9) 184 (41.5) 0.12
Bypass graft 2 (0.5) 2 (0.5) 1.00
Intravenous vasopressors 10 (2.3) 13 (2.9) 0.68
Baseline TIMI ﬂow in infarct vessel 0.05
0 or 1 329 (54.9) 332 (61.5)
2 99 (16.5) 68 (12.6)
3 171 (28.5) 140 (25.9)
Primary PCI procedure
No. of stents per lesion 1.32  0.64 1.26  0.53 0.34
Type of stent
Drug-eluting stent 401 (70.2) 359 (69.0) 0.79
Bare metal stent 172 (30.1) 162 (31.2) 0.76
Total stent length per lesion, mm 25.1  13.70 25.8  12.7 0.75
Average stent diameter, mm 3.1  0.5 3.2  0.7 0.06
Direct stenting 154 (27.0) 189 (36.4) 0.65
Maximal balloon pressure, atm 14.5  3.7 14.5  3.6 0.87
Overlapping stents implanted 135 (23.6) 110 (21.2) 0.33
Successful thrombus aspiration† 131 (30.7) 163 (36.5) 0.71
Final TIMI ﬂow in infarct vessel 0.78
0 or 1 4 (0.7) 6 (1.1)
2 20 (3.3) 18 (3.2)
3 577 (96.0) 531 (95.7)
Values are mean  SD or n (%). Patients grouped according to the loading dose, already on a daily
maintenance dose, or immediate post-procedure exposure. *p values pairwise (prasugrel þ
clopidogrel vs. prasugrel alone) from chi-square, Fisher exact test, or t test; p values from mixed
models accounting for lesions nested within patients for lesion-level data. †Visible thrombus
obtained.
PCI ¼ percutaneous coronary intervention; TIMI ¼ Thrombolysis In Myocardial Infarction.
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1069used in the group receiving clopidogrel and a subse-
quent loading dose of prasugrel compared with pra-
sugrel alone patients. At discharge, both groups of
patients were prescribed acetylsalicylic acid. More
patients receiving clopidogrel and a subsequent
loading dose of prasugrel than patients receiving
prasugrel alone were kept on prasugrel until hospital
discharge (96% and 88.9%, respectively; p < 0.001), a
difference that was no longer signiﬁcant at 1 year
(81.8% and 78.0%, respectively; p ¼ 0.19). A total of
53 of 420 patients receiving clopidogrel and a subse-
quent loading dose of prasugrel (12.4%) and 40 of 447
(8.9%) (p ¼ 0.10) prasugrel alone patients were at an
increased risk of bleeding and were therefore ful-
ﬁlling a formal contraindication to the use of prasu-
grel (Table 3).
CLINICAL OUTCOMES. Safety . At hospital discharge,
the primary safety endpoint of BARC types 3 to 5
bleeding was recorded in 1.4% of patients receiving
clopidogrel and a subsequent loading dose of prasu-
grel and 3.4% of prasugrel alone patients, respec-
tively (adjusted HR: 0.43; 95% CI: 0.17 to 1.08;
p ¼ 0.07) (Table 4). At 30 days, the primary safety
endpoint of BARC types 3 to 5 bleeding was recorded
in 1.9% of patients receiving clopidogrel and a sub-
sequent loading dose of prasugrel and 3.4% of
patients receiving prasugrel alone (adjusted HR: 0.57;
95% CI 0.25 to 1.30; p ¼ 0.18) (Table 5). Similarly, no
differences in TIMI major (1.2% vs. 1.8%) or TIMI
minor (0.7% vs. 1.6%), and GUSTO severe (0.5% vs.
1.3%) or GUSTO moderate (0.5% vs. 0.5%) bleeding
episodes were observed at 30 days (Table 5), and
there were no differences in terms of bleeding local-
ization (Table 6). To address potential differences in
bleeding risk between patients receiving clopidogrel
and a subsequent loading dose of prasugrel and those
receiving prasugrel alone at the time point of inclu-
sion, we assessed the HAS-BLED bleeding score in
both treatment groups and found no signiﬁcant dif-
ference but a trend toward a lower bleeding risk in
patients receiving prasugrel alone. When adjusting
the primary safety endpoint using the HAS-BLED
score, we found consistent results (BARC types 3 to
5 bleeding at 30 days: adjusted HR [clopidogrel and a
subsequent loading dose of prasugrel vs. prasugrel
alone]: 0.54; 95% CI: 0.23 to 1.27; p ¼ 0.16) (Online
Table 1).
One-year safety results are shown in Online
Table 2. The primary safety endpoint at 1 year was
observed in 3.9% of patients receiving clopidogrel
and a subsequent loading dose of prasugrel and 4.3%
of patients receiving prasugrel alone (adjusted HR:
0.91; 95% CI: 0.46 to 1.79; p ¼ 0.79).A comparison of patients receiving clopidogrel and
a subsequent loading dose of prasugrel with those
receiving clopidogrel only was not the primary focus of
this study; however, the 30-day outcomes are pro-
vided in Online Table 3. The frequency of the primary
endpoint of BARC types 3 to 5 bleeding was not
different between patients receiving clopidogrel and a
subsequent loading dose of prasugrel (1.9%) compared
with patients receiving clopidogrel alone (3%)
(adjusted HR: 0.87; 95% CI: 0.38 to 1.97; p ¼ 0.73).
EFFICACY. The frequency of the secondary efﬁcacy
endpoint, a composite of cardiac death, nonfatal
myocardial infarction, and stroke at hospital dis-
charge, occurred less frequently in the group
receiving clopidogrel and a subsequent loading dose
of prasugrel compared with the prasugrel alone
group (0.23% vs. 2.0%; adjusted HR: 0.07: 95%
TABLE 3 Periprocedural and Follow-up Medication
Clopidogrelþ
Prasugrel
(n ¼ 427)
Prasugrel
(n ¼ 447) p Value*
Medication during primary PCI
Unfractionated heparin 409 (95.8) 360 (80.7) <0.001
Bivalirudin 51 (11.9) 105 (23.5) <0.001
GP IIb/IIIa antagonist 124 (29.0) 178 (39.9) 0.001
Loading doses, mg <0.001
Clopidogrel alone 1 (0.2)† 0 (0.0)
300 38 (9.0)
600 380 (89.6)
Other 3 (0.7)
N/A 3 (0.7)
Prasugrel alone 3 (0.7)‡ 430 (96.2) <0.001
30 46 (10.8) 6 (1.4) <0.001
60 370 (86.9) 435 (97.3) <0.001
Other 8 (1.9) 3 (0.7) 0.14
N/A 2 (0.5) 3 (0.7) 1.00
Both clopidogrel and prasugrel 424 (99.1) 0 (0.0) <0.001
1 week double clopidogrel dose 1 (0.2) 0 (0) N/A
At discharge
Aspirin 423 (99.5) 440 (99.5) 1.00
Prasugrel 408 (96.0) 393 (88.9) <0.001
Clopidogrel 16 (3.8) 39 (8.8) 0.003
Any DAPT 422 (99.3) 433 (98.0) 0.14
At 30 days
Aspirin 414 (99.0) 432 (99.3) 0.72
Prasugrel 384 (91.9) 376 (86.4) 0.01
Clopidogrel 38 (9.1) 49 (11.3) 0.31
Any DAPT 413 (98.8) 420 (96.6) 0.04
At 1 year
Aspirin 392 (98) 412 (96.5) 0.209
Prasugrel 327 (81.8) 333 (78.0) 0.19
Clopidogrel 42 (10.5) 47 (11.0) 0.82
Any DAPT 362 (90.5) 376 (88.1) 0.26
High-risk patients (age $75 yrs or weight <60 kg, or
history of stroke/TIA)*§
n ¼ 53 n ¼ 40
Clopidogrel loading dose, mg n ¼ 52
300 2 (3.8)
600 48 (92.3)
Other 1 (1.9)
N/A 1 (1.9)
Prasugrel loading dose, mg n ¼ 53 n ¼ 38 0.680
30 1 (1.9) 0 (0.0) 1.000
60 50 (94.3) 37 (97.4) 0.638
Other 1 (1.9) 0 (0.0) 1.000
N/A 1 (1.9) 1 (2.6) 1.000
Values are n (%). Patients grouped according to the loading dose, already on daily maintenance dose MD,
or immediate post-procedure exposure. *p values (prasugrel þ clopidogrel vs. prasugrel alone) from chi-square
or Fisher exact test. †Already on maintenance dose of prasugrel. ‡Already on maintenance dose of clopidogrel.
Number of patients who received loading dose of prasugrel or clopidogrel. Excludes patients without any
loading. §Excludes 19 patients with the weight missing, but all 19 were assumed low risk because all 19 were
younger than 75 years of age and did not have a history of stroke.
DAPT ¼ dual antiplatelet therapy; GP ¼ glycoprotein; N/A ¼ not available; PCI ¼ percutaneous coronary
intervention; TIA ¼ transient ischemic attack.
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1070CI: 0.01 to 0.55; p ¼ 0.01) (Table 4). However, there
was no longer a difference observed at 30 days
(1.9% vs. 2.9%; adjusted HR: 0.66; 95% CI: 0.27 to1.62; p ¼ 0.36) (Table 5) between groups. No differ-
ences in individual endpoints such as death, cardiac
death, nonfatal MI, and stroke were observed at 30
days. There was no difference in the rate of deﬁnite or
probable stent thrombosis both at hospital discharge
and 30 days. One-year efﬁcacy data are shown in the
Online Table 2.
DISCUSSION
We report the results of the largest retrospective
cohort study of prospectively collected data in-
vestigating the clinical safety (and efﬁcacy) of
concomitant prasugrel and clopidogrel loading com-
pared with prasugrel loading alone in patients with
STEMI undergoing primary PCI. At hospital discharge
and 30-day follow-up, the concomitant administration
of prasugrel and clopidogrel loading doses was not
associated with an increased risk of severe bleeding
as assessed by the primary safety parameter, BARC
types 3, 4, and 5 bleeding. Likewise, no differences
in TIMI major or minor and GUSTO severe or mod-
erate bleeding were observed. In addition, a similar
efﬁcacy of the 2 treatment groups was conﬁrmed.
Pretreatment with P2Y12 inhibitors in STEMI pa-
tients is recommended by guidelines (6). With regard
to the choice of agent, current guidelines indicate a
preference for novel P2Y12 inhibitors over clopidogrel
(7,8) because of their more rapid, more potent, and
consistent inhibition of platelet aggregation as well as
improved clinical outcomes (4,15). Thus, prasugrel
has been shown to be superior to clopidogrel in the
prevention of recurrent ischemic events in patients
with ACS and known coronary anatomy at the
expense of an increased risk of TIMI major bleeding in
the large-scale TRITON-TIMI 38 trial (Trial to Assess
Improvement in Therapeutic Outcomes by Opti-
mizing Platelet Inhibition with Prasugrel–Thrombol-
ysis In Myocardial Infarction 38) (16). Prasugrel was
effective among the subgroup of STEMI patients,
potentially related to the high residual on-treatment
platelet reactivity in clopidogrel-treated STEMI pa-
tients (17). However, many patients with STEMI are
still pre-treated with clopidogrel at the time of ﬁrst
medical contact before primary PCI, posing the
question of whether these patients should undergo
additional loading with prasugrel followed by prasu-
grel maintenance or be maintained on clopidogrel
alone. Although one would expect at least similar ef-
ﬁcacy, concerns relate to an excess risk of bleeding
with the double-loading regimen. As major bleeding is
recognized to affect clinical outcomes including sur-
vival (18), any beneﬁt in terms of efﬁcacy may be
camouﬂaged by the increased risk of bleeding.
TABLE 4 Clinical Outcomes at Hospital Discharge
C þ P
Events
(n ¼ 427)
P
Events
(n ¼ 447)
Crude Analyses IPTW Adjusted Analyses
CP vs. P, HR (95% CI) p Value CP vs. P, HR (95% CI) p Value
BARC types 3–5 bleeding 6 (1.41) 15 (3.36) 0.44 (0.18–1.08) 0.07 0.43 (0.17–1.08) 0.07
Cardiac death, nonfatal myocardial infarction, or stroke 1 (0.23) 9 (2.01) 0.14 (0.02–0.99) 0.05 0.07 (0.01–0.55) 0.01
Death 1 (0.23) 4 (0.89) 0.31 (0.04–2.30) 0.25
Cardiac death 1 (0.23) 3 (0.67) 0.40 (0.05–3.11) 0.38
Myocardial infarction 0 (0.00) 4 (0.89) 0.21 (0.02–1.79) 0.13
Any revascularization 2 (0.47) 6 (1.34) 0.35 (0.08–1.60) 0.18
Deﬁnite stent thrombosis 0 (0.00) 2 (0.45) 0.35 (0.04–3.35) 0.50
Deﬁnite or probable stent thrombosis 0 (0.00) 6 (1.34) 0.15 (0.02–1.21) 0.03
Stroke 0 (0.00) 2 (0.45) 0.35 (0.04–3.35) 0.50
BARC bleeding type
3 5 (1.17) 13 (2.91) 0.42 (0.15–1.12) 0.08
3a 3 (0.70) 7 (1.57) 0.45 (0.12–1.73) 0.25
3b 2 (0.47) 6 (1.34) 0.37 (0.08–1.66) 0.20
3c 0 (0.00) 0 (0.00)
4 0 (0.00) 1 (0.22) 0.52 (0.05–5.71) 1.00
5 1 (0.23) 1 (0.22) 1.07 (0.09–12.40) 0.96
TIMI bleeding
Major 3 (0.70) 8 (1.79) 0.42 (0.13–1.44) 0.17
Minor 3 (0.70) 7 (1.57) 0.45 (0.12–1.73) 0.25
GUSTO bleeding
Severe 1 (0.23) 6 (1.34) 0.18 (0.02–1.40) 0.10
Moderate 1 (0.23) 2 (0.45) 0.58 (0.07–4.93) 0.61
Values are n (%) unless otherwise indicated. Incidence rate ratios (95% CI), and p Values from Poisson regressions (crude analyses) or Poisson regressions weighted by inverse probability of
treatment weighted and adjusted for study (COMFORTABLE or BIOMARKER), insulin-dependent diabetes, history of coronary artery bypass grafting, anemia, thrombocytopenia, Killip III or IV,
left ventricular ejection fraction after 10 times multiple imputation of missing values using chained equations (adjusted analyses). Risk ratio with continuity correction and Fisher exact test
p values are reported in case of zero events in 1 treatment group. The inverse probability of treatment weighted was calculated using the following baseline variables: age, sex, diabetes,
hypercholesterolemia, current smoker, family history of coronary artery disease, previous coronary artery bypass grafting, pain onset within 24 h, acute myocardial infarction location, stent
type, and procedural medications including unfractionated heparin, bivalirudin, low molecular weight heparin, GPII/IIIa antagonists.
BARC ¼ Bleeding Academic Research Consortium; C ¼ clopidogrel; CI ¼ conﬁdence interval; CP ¼ clopidogrel and a subsequent prasugrel loading dose; HR ¼ hazard ratio; IPTW ¼ inverse
probability of treatment weighted; P ¼ prasugrel.
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1071Given this background, our ﬁndings showing no
increase in bleeding rates according to any bleeding
classiﬁcation including BARC types 3 to 5 bleeding,
major or minor TIMI, and GUSTO severe or moderate
irrespective of loading regimen are reassuring and
suggest a wide range of safety of these agents as used
in routine clinical practice. The notion that addi-
tional loading with potent platelet inhibitors appears
safe among STEMI patients undergoing primary PCI
is further substantiated by the concomitant use of
glycoprotein IIB/IIIa antagonists during primary PCI
in 29% of patients in the group receiving clopidogrel
and a subsequent loading dose of prasugrel and 40%
of patients in the prasugrel alone group.
Prasugrel inhibits platelet activation through
irreversible P2Y12 receptor blockade with a mecha-
nism similar to that of clopidogrel. Four pharmaco-
dynamic studies have investigated the switch
from clopidogrel to prasugrel under various circum-
stances. The SWAP (Switching Anti Platelet) study
assessed the effect of a prasugrel loading dose in
patients receiving a clopidogrel maintenance dosefor at least 10 days (19). An additional loading dose
resulted in a further signiﬁcant reduction in platelet
function within 2 h of administration. In the
ACAPULCO (Prasugrel Compared With High-Dose
Clopidogrel in acute coronary syndrome) study, a
prasugrel maintenance dose regimen resulted in
signiﬁcantly greater platelet inhibition compared
with clopidogrel at a double maintenance dose (180
mg) after a loading dose of 900 mg clopidogrel in
both groups (5). Two recent studies investigated the
effect of a concomitant loading dose with both clo-
pidogrel and prasugrel compared with prasugrel
alone in ACS patients. An observational study per-
formed in 47 STEMI patients observed a profound
inhibition of platelet aggregation after concomitant
loading with both clopidogrel and prasugrel (median
[interquartile range]: 10 [8 to 31] platelet reactivity
units (PRUs), which, however, was similar to that of
patients loaded with prasugrel alone (median
[interquartile range]: 9 [6 to 60] PRUs; p ¼ 0.916),
suggesting no excess in platelet inhibition after dual
loading (20). In the TRIPLET (Transferring From
TABLE 5 Clinical Outcomes at 30 Days
CP
Events
(n ¼ 427)
P
Events
(n ¼ 447)
Crude Analyses IPTW Adjusted Analyses
CP vs. P, HR (95% CI) p Value CP vs. P, HR (95% CI) p Value
BARC types 3–5 bleeding 8 (1.9) 15 (3.4) 0.57 (0.24–1.34) 0.20 0.57 (0.25–1.30) 0.18
Cardiac death, nonfatal myocardial infarction, or stroke 8 (1.9) 13 (2.9) 0.70 (0.29–1.70) 0.44 0.66 (0.27–1.62) 0.36
Death 5 (1.2) 6 (1.4) 0.99 (0.30–3.28) 0.99 1.05 (0.27–4.10) 0.95
Cardiac death 5 (1.2) 5 (1.1) 1.18 (0.34–4.10) 0.78 1.05 (0.27–4.10) 0.95
Myocardial infarction 2 (0.5) 5 (1.1) 0.41 (0.08–2.11) 0.28 0.57 (0.14–2.21) 0.41
Any revascularization 9 (2.1) 9 (2.0) 1.06 (0.42–2.70) 0.90 1.46 (0.49–4.32) 0.50
Deﬁnite ST 2 (0.5) 2 (0.4) 1.07 (0.15–7.71) 0.95 0.98 (0.22–4.39) 0.98
Deﬁnite or probable ST 5 (1.2) 7 (1.6) 0.82 (0.26–2.61) 0.74 0.89 (0.28–2.87) 0.85
Stroke 1 (0.2) 3 (0.7) 0.46 (0.05–4.38) 0.50 0.47 (0.04–5.98) 0.56
BARC bleeding type
3 7 (1.6) 13 (2.9) 0.57 (0.22–1.43) 0.23 0.61 (0.25–1.48) 0.28
3a 3 (0.7) 7 (1.6) 0.45 (0.12–1.76) 0.25 0.44 (0.11–1.75) 0.24
3b 4 (0.9) 6 (1.3) 0.71 (0.20–2.53) 0.59 0.81 (0.25–2.67) 0.74
3c 0 (0.0) 0 (0.0)
4 0 (0.0) 1 (0.2) 0.52 (0.05–5.71) 1.00
5 1 (0.2) 2 (0.5) 0.49 (0.04–5.44) 0.56 0.33 (0.03–4.35) 0.40
TIMI bleeding
Major 5 (1.2) 8 (1.8) 0.67 (0.22–2.08) 0.49 0.68 (0.24–1.92) 0.46
Minor 3 (0.7) 7 (1.6) 0.45 (0.12–1.76) 0.25 0.44 (0.11–1.75) 0.24
GUSTO bleeding
Severe 2 (0.5) 6 (1.3) 0.35 (0.07–1.74) 0.20 0.27 (0.06–1.25) 0.09
Moderate 2 (0.5) 2 (0.5) 1.07 (0.15–7.71) 0.95 1.73 (0.28–10.51) 0.55
Values are n (%) unless otherwise indicated. Incidence rate ratios (95% conﬁdence interval CI) and p values from Poisson regressions (crude analyses) or Poisson regressions weighted by the
inverse probability of treatment weighted and adjusted for study (COMFORTABLE or BIOMARKER), insulin-dependent diabetes, history of coronary artery bypass grafting, anemia, throm-
bocytopenia, Killip III or IV, left ventricular ejection fraction after 10 times multiple imputation of missing values using chained equations (adjusted analyses). Risk ratio with continuity
correction and Fisher exact test p values are reported, in case of zero events in one treatment group. The inverse probability of treatment weighted was calculated using the following baseline
variables: age, sex, diabetes, hypercholesterolemia, current smoker, family history of coronary artery disease, previous coronary artery bypass grafting, pain onset within 24 h, acute
myocardial infarction location, stent type, and procedural medications including unfractionated heparin, bivalirudin, low molecular weight heparin, glycoprotein II/IIIa antagonists
ST ¼ stent thrombosis; other abbreviations as in Tables 2 and 4.
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1072Clopidogrel Loading Dose to Prasugrel Loading
Dose in Acute Coronary Syndrome PatiEnTs study,
282 ACS patients were included to assess the phar-
macodynamic response to prasugrel alone compared
with prasugrel 60mg or 30mg added<24 h to a loading
dose of 600 mg clopidogrel. Consistent with theTABLE 6 Bleeding Location at 30-Day Follow-up
Location CP (n ¼ 9) P (n ¼ 18)
p Value
(CP vs. P)
0.50
Intracranial 0 (0) 0 (0)
Intraocular 0 (0) 0 (0)
Retroperitoneal 0 (0) 4 (22)
Vascular access site 6 (67) 5 (28)
Gastrointestinal 1 (11) 2 (11)
Genitourinary 1 (11) 3 (17)
Pulmonary 0 (0) 1 (6)
Pericardial 0 (0) 1 (4)
Other 1 (11) 2 (12)
Values are n (%).
Abbreviations as in Table 4.aforementioned observational study, no signiﬁcant
increase in PRUs was observed with prasugrel (57.9
PRUs) compared with prasugrel in addition to a
clopidogrel loading dose (35.6 PRUs), a least-square
mean difference (95% CI) of 22.2 (11.1 to 55.5)
(p ¼ 0.19) (21).
The absence of excessive levels of platelet inhi-
bition observed in pharmacodynamic studies after
the administration of a concomitant loading dose
of prasugrel in addition to clopidogrel compared
with a prasugrel loading dose alone provides a solid
explanation for the absence of an excess in clinically
overt bleeding in the treatment group receiving a
double loading. The treatment with a full loading
dose of prasugrel alone almost completely saturates
the P2Y12 receptor according to pharmacodynamic
studies (22). In patients who have been pretreated
with a full loading dose of clopidogrel, the addition
of a loading dose of prasugrel will occupy the
remaining P2Y12 receptor sites not completely satu-
rated by the active metabolite of clopidogrel. How-
ever, the difference between a strategy of loading
with prasugrel alone compared with additional
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1073prasugrel loading after a clopidogrel loading dose
will result only in a minor difference in actual
platelet inhibition.
Radial access is associated with a lower risk of
access site bleeding in STEMI patients (23). In the
present study, only 2 centers preferentially used a
radial access route, limited to 155 patients. When we
performed a sensitivity analysis excluding the 2 cen-
ters preferentially using a radial access route, we
found similar hazards of bleeding between groups.
In the present study, the dual-loading regimen of
prasugrel and clopidogrel as well as loading with pra-
sugrel alone were associated with a similar efﬁcacy as
indicated by the secondary composite endpoint of
cardiac death, myocardial infarction, and stroke. In
addition, no differences in deﬁnite or probable stent
thrombosis were noted.
The comparison of patients receiving clopidogrel
and a subsequent loading dose of prasugrel with pa-
tients receiving only a clopidogrel loading dose was
not the primary focus of this analysis in view of the
available evidence of the TRITON-TIMI-38. Moreover,
this comparison is scientiﬁcally less valid as it was
inﬂuenced by unmeasured confounding such that
patients with a high bleeding risk did not receive a
concomitant loading dose of prasugrel. However,
outcomes conﬁrm the absence of an excess in
bleeding in patients receiving clopidogrel and a sub-
sequent loading dose of prasugrel compared with
those receiving only clopidogrel.
STUDY LIMITATIONS. The results of this observa-
tional, nonrandomized study have to be interpreted
in the light of the following limitations. Patients were
not randomly allocated to treatment groups, and
ﬁndings should therefore be carefully interpreted. As
the treatment allocation was at the discretion of the
operator, patients with high bleeding risk were pre-
vented from receiving a double-loading dose. Even
after statistical adjustment for baseline clinical char-
acteristics, HRs indicated a higher bleeding risk (with
CIs crossing the line of no difference) in patients
receiving prasugrel alone compared with patients
receiving clopidogrel and a subsequent loading dose
of prasugrel. To further explore a potential difference
in the baseline bleeding risk, we assessed the HAS-
BLED bleeding score in all patients and found a
trend toward a higher bleeding risk in patients
receiving prasugrel alone compared with those
receiving clopidogrel and a subsequent loading dose
of prasugrel. When adjusting the primary safety
endpoint results for the HAS-BLED bleeding score,
results remained robust. Despite pre-speciﬁed rec-
ommendations regarding the use of prasugrel andclopidogrel in STEMI patients included in the present
study, the ﬁnal decision was left to the discretion of
the treating physician. The sample size of this anal-
ysis was not on the basis of a pre-speciﬁed power
calculation, and therefore the absence of differences
in bleeding events between groups may reﬂect the
lack of sufﬁcient power. The number of bleeding
events was low, with a total of 24 bleeding events (8
in those receiving clopidogrel and a subsequent
loading dose of prasugrel and 15 in those receiving
prasugrel alone). As a result, CIs describing differ-
ences in the primary safety endpoint were wide,
indicating no signiﬁcant difference between groups.
Notwithstanding, this is thus far the largest observa-
tional cohort, including 428 patients with concomi-
tant loading of prasugrel and clopidogrel whose
relevance is magniﬁed due to the lack of randomized
clinical trials addressing the safety of dual loading-
dose regimens. In addition, only a few exclusion
criteria were applied in both studies and 12 interna-
tional sites participated, which increases the gener-
alizability of the results.
CONCLUSIONS
The ﬁndings of our study are clinically relevant as
many STEMI patients referred for primary PCI are
pre-treated with clopidogrel in routine clinical
practice. On the basis of the presented data, the
addition of a prasugrel loading dose in clopidogrel
pre-treated patients may be considered to achieve
more rapid, more potent, and consistent inhibition
of platelet aggregation. This treatment strategy does
not seem to result in excess bleeding although it has
the potential to lower the risk of ischemic adverse
events, as previously shown. Notwithstanding, dose
adaptations and attention to relative and absolute
contraindications for the use of prasugrel should
be carefully weighed in the therapeutic decision
process.
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PERSPECTIVES
WHAT IS KNOWN? Pharmacodynamic studies do not
show an excess in platelet inhibition after double loading
doses of clopidogrel and prasugrel. However, safety data
regarding a double-loading regimen with prasugrel and
clopidogrel are not available.
WHAT IS NEW? This is the largest observational study
in STEMI patients undergoing primary PCI and suggests
that a loading dose of prasugrel in STEMI patients pre-
loaded with clopidogrel—a scenario frequently encoun-
tered in clinical practice—is not associated with an
increased risk of major bleeding events.
WHAT IS NEXT? Further studies are needed to corrob-
orate these ﬁndings to determine the optimal dual
antiplatelet therapy loading strategy in STEMI patients.
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